Primary source: BA/BE
CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.
This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.
MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Transition from manual/offline submissions to mandatory online filings through the SUGAM portal for all vaccine-related post-approval changes.
Safety-related variations and updates to product information for vaccines in India must now be processed through the SUGAM portal, requiring MAHs to update their submission procedures.
MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.
The Central Drugs Standard Control Organisation (CDSCO) has implemented a new requirement mandating that all applications related to post-approval changes for registration certificates and import licenses of human vaccines and anti-sera be submitted exclusively through the SUGAM online portal. This shift from manual to online submissions includes safety-related updates and variations, necessitating that Marketing Authorization Holders (MAHs) revise their submission procedures accordingly.
What changed: CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.
Why it matters: This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.
Practical implication: MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
